CAD - Coronary Artery DiseaseCABGERASMedicine, Chinese Traditional
Investigational drug(s) / intervention(s)
FZYX
FZYX: Intervention: Fuzheng Yangxin Formula granules combined with routine postoperative management. The formula consists of Radix Ginseng 20 g, processed Radix Aconiti Lateralis Preparata 10 g (pre-decocted), Radix Astragali 30 g, Radix Ophiopogonis 20 g, Radix Angelicae Sinensis 15 g, Radix Rehmanniae 15 g, Radix Rhodiolae 30 g, Radix Notoginseng powder 6 g (mixed with warm water for oral use). Participants take the granules orally for 7 consecutive days after CABG.
Study summary
This study aims to evaluate the efficacy and safety of Fuzheng Yangxin Formula (FZYXF) in the treatment of qi-yin deficiency syndrome after coronary artery bypass grafting (CABG), formulate an integrated Chinese and Western medicine rehabilitation protocol, develop special proprietary Chinese medicines for postoperative patients, establish a postoperative rehabilitation database, and promote the standardized application and achievement transformation of integrated Chinese and Western medicine therapy in cardiac surgery.
Eligibility
Sex
ALL
Min age
20 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria:
-Patients who have undergone coronary artery bypass grafting (CABG) and present with postoperative qi-yin deficiency syndrome.
Exclusion Criteria:
* Patients with hypersensitivity to any components of Fuzheng Yangxin Formula granules.
* Patients with fever or common cold after surgery.
* Patients with severe postoperative liver and kidney dysfunction.
* Patients who receive concurrent valve surgery or other intracardiac operations
* Patients with end-stage malignant tumors
* Patients with uncontrolled infection or bleeding
* Patients with progressive degenerative systemic diseases, such as severe trauma, multiple organ failure and other severe impairment of vital organ function including severely damaged liver function
* Patients with severe heart failure or cardiogenic shock who cannot tolerate treatment.
Primary outcome measure(s)
Score of physical activity limitation dimension in the Seattle Angina Questionnaire (SAQ) at 7 days after medication — 7 days after operation Measured using the Seattle Angina Questionnaire
Trial sites (1)
Facility
City
Region
Status
Peking University 3rd hospital
Beijing
China
More Peking University Third Hospital trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.